Overview

PK of JULUCA in Hemodialysis

Status:
Recruiting

Trial end date:
2022-03-31

Target enrollment:

Participant gender:

Summary

This study will compare the pharmacokinetics of the component drugs in JULUCA, and HIV combination treatment pill, in HIV-negative patients who require hemodialysis with those with normal renal function.

Phase:

Phase 4

Details

Lead Sponsor:

Indiana University

Treatments:

Dolutegravir, rilpivirine drug combination